Improving nitric oxide levels to help treat preeclampsia
Official title: Restoration of reduced nitric oxide bioavailability in Preeclampsia
Funded at Beth Israel Deaconess Medical Center · NIH-10870378 · Data updated 2026-11-12
This study is looking at a new medication called AKT-1005 that could help treat preeclampsia, a serious condition during pregnancy, by making sure it works well in the body, so it can better protect both moms and their babies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $262,808 |
| NIH project number | 1R21HD115117-01 |
| Project ID | NIH-10870378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pregnant individuals diagnosed with preeclampsia.
✕Less likely to help
Patients who are not pregnant or those without a diagnosis of preeclampsia may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for preeclampsia, a serious pregnancy complication characterized by high blood pressure and potential harm to both mother and baby. The team is working on a drug called AKT-1005, which has shown promise in laboratory models but faces challenges with its solubility and stability. To address these issues, they will create and test new formulations of AKT-1005 to ensure it can be effectively delivered in the body. If successful, this treatment could significantly improve outcomes for pregnant individuals affected by preeclampsia.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that reduces the risks associated with preeclampsia for pregnant individuals.
How similar studies have gone: Previous research has shown promise in using nitric oxide donors for treating preeclampsia, indicating that this approach has potential based on earlier findings.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Zsengeller, Zsuzsanna Kinga — Beth Israel Deaconess Medical Center
- Study coordinator: Zsengeller, Zsuzsanna Kinga
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
-
Folate Receptor Beta and its Role in Preeclampsia
This study explores how a protein called folate receptor beta on placental immune cells may drive or worsen preeclampsia in pregnancy, with hopes of finding new ways to prevent or treat the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.